Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A pharmacokinetics study of dextroamphetamine (d-AMPH) from abuse-deterrent dextroamphetamine sulfate immediate release (ADAIR) 10 mg versus ADAIR administered orally

Next Previous
X
Search
Trial Profile

A pharmacokinetics study of dextroamphetamine (d-AMPH) from abuse-deterrent dextroamphetamine sulfate immediate release (ADAIR) 10 mg versus ADAIR administered orally

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 24 Aug 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dexamfetamine (Primary) ; Dexamfetamine (Primary)
  • Indications Attention-deficit hyperactivity disorder; Narcolepsy
  • Focus Pharmacokinetics

    • Most Recent Events

    • 25 Jan 2021 New trial record
    • 19 Jan 2021 According to a Vallon Pharma media release, result presented at the 2021 American Professional Society of ADHD and Related Disorders (APSARD) Annual Meeting.
    • 19 Jan 2021 Results presented in a Vallon Pharma Media Release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top